| Pharmaceutical Information |
| Drug Name |
Didanosine |
| Drug ID |
BADD_D00661 |
| Description |
A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. Didanosine is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA by binding to reverse transcriptase; ddI is then metabolized to dideoxyadenosine triphosphate, its putative active metabolite. |
| Indications and Usage |
For use, in combination with other antiretroviral agents, in the treatment of HIV-1 infection in adults. |
| Marketing Status |
approved |
| ATC Code |
J05AF02 |
| DrugBank ID |
DB00900
|
| KEGG ID |
D00296
|
| MeSH ID |
D016049
|
| PubChem ID |
135398739
|
| TTD Drug ID |
D06FDR
|
| NDC Product Code |
65015-794; 65862-400; 65862-322; 68554-0012 |
| UNII |
K3GDH6OH08
|
| Synonyms |
Didanosine | Dideoxyinosine | 2',3'-Dideoxyinosine | 2',3' Dideoxyinosine | ddI (Antiviral) | Videx | NSC-612049 | NSC 612049 | NSC612049 |
|
| Chemical Information |
| Molecular Formula |
C10H12N4O3 |
| CAS Registry Number |
69655-05-6 |
| SMILES |
C1CC(OC1CO)N2C=NC3=C2N=CNC3=O |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
|
|
| ADR Term |
ADReCS ID |
ADR Frequency (FAERS)
|
ADR Severity Grade (FAERS)
|
ADR Severity Grade (CTCAE)
|
|
|
|
